Stevanato Group Investor Relations

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients.

Latest News

Stevanato Group Announces Expansion of Corporate Headquarters

View Press Release

Stevanato Group Reports Strong Third Quarter 2021 Revenue and Financial Results and Updates Full Year 2021 Guidance

View Press Release

Stevanato Group to Report Third Quarter Financial Results on November 9

View Press Release

Stevanato Group Wins Pharma Innovation Award For AI-ready Vision Robot Unit (VRU)

View Press Release

Latest Financial Results

Q3 2021

Quarter Ended Sep 30, 2021

IR Contacts

Company

Stevanato Group S.p.A.
Via Molinella 17
Piombino Dese, Padua 35017
Italy

Investor Relations

Lisa Miles
Senior Vice President, Investor Relations
IR@stevanatogroup.com

Transfer Agent

Computershare Trust Company, N.A.
150 Royall Street
Canton, MA 02021